

Maria I Toki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5781579/publications.pdf>

Version: 2024-02-01

33
papers

1,932
citations

471061

17
h-index

414034

32
g-index

34
all docs

34
docs citations

34
times ranked

3770
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2021, 149, 277-286.	2.3	7
2	Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. <i>Npj Precision Oncology</i> , 2021, 5, 45.	2.3	11
3	COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. <i>Infection</i> , 2021, 49, 889-905.	2.3	62
4	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	3.2	38
5	The value of open-source clinical science in pandemic response: lessons from ISARIC. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1623-1624.	4.6	21
6	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
7	The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making. <i>Lung Cancer</i> , 2020, 146, 127-133.	0.9	19
8	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2084-2096.	0.5	48
9	High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling. <i>Clinical Cancer Research</i> , 2019, 25, 5503-5512.	3.2	117
10	Immune Checkpoint Inhibitor-Associated Pericarditis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1102-1108.	0.5	72
11	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 4663-4673.	3.2	210
12	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 656-666.	15.2	461
13	Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. <i>Laboratory Investigation</i> , 2019, 99, 107-117.	1.7	91
14	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	3.2	106
15	An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients. <i>Npj Breast Cancer</i> , 2018, 4, 6.	2.3	7
16	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	3.2	150
17	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	2.3	36
18	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.	0.5	78

#	ARTICLE	IF	CITATIONS
19	Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 12015-12015.	0.8	1
20	Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).. Journal of Clinical Oncology, 2018, 36, 12002-12002.	0.8	0
21	Proof of the quantitative potential of immunofluorescence by mass spectrometry. Laboratory Investigation, 2017, 97, 329-334.	1.7	35
22	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research, 2017, 23, 5202-5209.	3.2	99
23	P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC. Journal of Thoracic Oncology, 2017, 12, S813-S814.	0.5	0
24	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology, 2017, 3, 256.	3.4	164
25	Abstract 3810: Validation of novel high-plex protein spatial profiling quantitation based on NanoString's Digital Spatial Profiling (DSP) technology with quantitative fluorescence (QIF). Cancer Research, 2017, 77, 3810-3810.	0.4	5
26	Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations.. Journal of Clinical Oncology, 2017, 35, 9076-9076.	0.8	3
27	PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, S287.	0.5	2
28	EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1901-1911.	0.5	14
29	Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports, 2016, 16, 457-471.	2.9	48
30	Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 11610-11610.	0.8	2
31	Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 9040-9040.	0.8	2
32	Hypersensitivity reactions associated with oxaliplatin and their clinical management. Expert Opinion on Drug Safety, 2014, 13, 1545-1554.	1.0	8
33	Risk determination for pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 289-91.	1.5	2